日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records Study

接受 Galcanezumab 或传统预防性偏头痛药物治疗的患者每月头痛次数和严重程度:一项为期 24 个月的索赔和电子健康记录研究

Varnado, Oralee J; Vu, Michelle; Kim, Gilwan; Hoyt, Margaret; Buysman, Erin; Nayyar, Abhinav; Anand, Shikha; Viktrup, Lars

Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME (US) study

使用多种进展定义评估偏头痛进展的发生率和风险因素:纵向 OVERCOME(美国)研究的结果

Buse, Dawn C; Muenzel, E Jolanda; Zagar, Anthony J; Mehrabadi, Ali Sheikhi; Shapiro, Robert E; Kim, Gilwan; Ashina, Sait; Nicholson, Robert A; Lipton, Richard B

Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis

美国回顾性索赔分析:成人发作性偏头痛患者接受 Galcanezumab 与 Rimegepant 治疗后的医疗资源利用、成本和治疗中断情况

Kim, Gilwan; Hoyt, Margaret; Zakharyan, Armen; Durica, Jennifer; Wallem, Alexandra; Viktrup, Lars

Opioid Use among People with Migraine: Results of the OVERCOME (US) Study

偏头痛患者阿片类药物使用情况:OVERCOME(美国)研究结果

Ashina, Sait; Johnston, Elizabeth; Muenzel, E Jolanda; Kim, Gilwan; Buse, Dawn C; Reed, Michael L; Shapiro, Robert E; Hutchinson, Susan; Zagar, Anthony J; Nicholson, Robert A; Lipton, Richard B

Treatment Patterns and Healthcare Resource Utilization by Gender and Migraine Frequency in Adult Patients Receiving Galcanezumab Versus Standard of Care Preventive Medications Over 24 months: A United States Retrospective Claims Study

美国回顾性索赔研究:接受 Galcanezumab 治疗的成年患者与接受标准预防性药物治疗的成年患者在 24 个月内的治疗模式和医疗资源利用情况(按性别和偏头痛发作频率划分)

Varnado, Oralee J; Vu, Michelle; Buysman, Erin K; Kim, Gilwan; Allenback, Gayle; Hoyt, Margaret; Trenz, Helen; Cao, Feng; Viktrup, Lars

Patients' Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)

患者在开始使用降钙素基因相关肽(CGRP)单克隆抗体(mAb)预防偏头痛之前的漫长旅程中的经历

Seng, Elizabeth; Lampl, Christian; Viktrup, Lars; Lenderking, William R; Karn, Hayley; Hoyt, Margaret; Kim, Gilwan; Ruff, Dustin; Ossipov, Michael H; Vincent, Maurice

Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States

在美国,开始使用加尔卡奈珠单抗或标准预防性偏头痛治疗后 24 个月内医疗资源利用情况和直接成本

Varnado, Oralee J; Vu, Michelle; Buysman, Erin; Kim, Gilwan; Allenback, Gayle; Hoyt, Margaret; Trenz, Helen; Cao, Feng; Viktrup, Lars

A Real-world Claims Data Analysis of Meningococcal Serogroup B Vaccine Series Completion and Potential Missed Opportunities in the United States

美国脑膜炎球菌B群疫苗全程接种完成情况及潜在错失机会的真实世界索赔数据分析

Packnett, Elizabeth R; Zimmerman, Nicole M; Kim, Gilwan; Novy, Patricia; Morgan, Laura C; Chime, Nnenna; Ghaswalla, Parinaz

Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis

接受多发性硬化症疾病缓解治疗的在职患者的生产力损失及相关成本

Bonafede, Machaon; Mehta, Rina; Kim, Gilwan; Sruti, Ila; Tian, Marc; Pelletier, Corey; Goldfarb, Neil

Costs of Disease Relapses Among Individuals with Granulomatosis, with Polyangiitis, or Microscopic Polyangiitis in the United States

美国肉芽肿性多血管炎或显微镜下多血管炎患者疾病复发的成本

Kong, Amanda M; Kim, Gilwan; Michalska, Margaret; Best, Jennie H